Currently, almonertinib, a third-generation EGFR-TKI, was approved by NMPA (China) in 2020 for the treatment of advanced NSCLC patients with EGFR-TKI resistance progression after treatment and EGFR T790M mutation positivity. This evidence concerns the gene EGFR and non-small cell lung carcinoma.